Cannabinoid type 1 receptor antagonists modulate transport activity of multidrug resistance-associated proteins MRP1, MRP2, MRP3, and MRP4

Drug Metabolism and Disposition

Volumn 39, Issue 7, 2011, Pages 1294-1302

  Wittgen, Hanneke G M ^a   Van Den Heuvel, Jeroen J M W ^a   Van Den Broek, Petra H H ^a   Dinter Heidorn, Heike ^b   Koenderink, Jan B ^a   Russel, Frans G M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ABBOTT GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIARYLPYRAZOLINE DERIVATIVE; ADENOSINE TRIPHOSPHATE; CANNABINOID 1 RECEPTOR ANTAGONIST; ESTRADIOL 17 GLUCURONIDE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; RECOMBINANT PROTEIN; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL MEMBRANE TRANSPORT; CELL VACUOLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; HORMONE TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TARGETING; RAT;

BLOTTING, WESTERN; CELL LINE; CHROMATOGRAPHY, LIQUID; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PROTEIN TRANSPORT; RECEPTOR, CANNABINOID, CB1; TANDEM MASS SPECTROMETRY;

EID: 79959482544     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.037812     Document Type: Article

References (40)

1. Akita H, Suzuki H, Hirohashi T, Takikawa H, and Sugiyama Y (2002) Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. Pharm Res 19:34-41. (Pubitemid 34075104)
2. Amundsen R, Asberg A, Robertsen I, Vethe NT, Bergan S, Hartmann A, and Midtvedt K (2009) Rimonabant affects cyclosporine A, but not tacrolimus pharmacokinetics in renal transplant recipients. Transplantation 87:1221-1224.
3. Bakos E, Evers R, Sinkó E, Váradi A, Borst P, and Sarkadi B (2000) Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 57:760-768. (Pubitemid 30183717)
4. Barna I, Till I, and Haller J (2009) Blood, adipose tissue and brain levels of the cannabinoid ligands WIN-55,212 and SR-141716A after their intraperitoneal injection in mice: compound-specific and area-specific distribution within the brain. Eur Neuropsychopharmacol 19:533-541.
5. Bifulco M, Santoro A, Laezza C, and Malfitano AM (2009) Cannabinoid receptor CB1 antagonists: state of the art and challenges. Vitam Horm 81:159-189.
6. Bodó A, Bakos E, Szeri F, Varadi A, and Sarkadi B (2003a) Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J Biol Chem 278:23529-23537. (Pubitemid 36830172)
7. Bodó A, Bakos E, Szeri F, Váradi A and Sarkadi B (2003b) The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett 140-141:133-143. (Pubitemid 36378931)
8. Boyd ST and Fremming BA (2005) Rimonabant - a selective CB1 antagonist. Ann Pharmacother 39:684-690. (Pubitemid 40396623)
9. Chen ZS, Lee K, and Kruh GD (2001) Transport of cyclic nucleotides and estradiol 17-β-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 276:33747-33754.
10. Conrad S, Kauffmann HM, Ito K, Deeley RG, Cole SP, and Schrenk D (2001) Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J Hum Genet 46:656-663. (Pubitemid 33134743)
11. Di Marzo V (2008) CB1 receptor antagonism: biological basis for metabolic effects. Drug Discov Today 13:1026-1041.
12. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, and Russel FG (2007) Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther 320:229-235. (Pubitemid 46025738)
13. El-Sheikh AA, van den Heuvel JJ, Krieger E, Russel FG, and Koenderink JB (2008) Functional role of arginine 375 in transmembrane helix 6 of multidrug resistance protein 4 (MRP4/ABCC4). Mol Pharmacol 74:964-971.
14. Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, and Borst P (2000) Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer 83:375-383. (Pubitemid 30453579)
15. Flens MJ, Zaman GJ, van der Valk P, Izquierdo MA, Schroeijers AB, Scheffer GL, van der Groep P, de Haas M, Meijer CJ, and Scheper RJ (1996) Tissue distribution of the multidrug resistance protein. Am J Pathol 148:1237-1247. (Pubitemid 26111082)
16. Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, and Otsubo K (2001) Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/CMOAT, in healthy Japanese subjects. Pharmacogenetics 11:175-184. (Pubitemid 32216128)
17. Jones D (2008) End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat Rev Drug Discov 7:961-962.
18. Kanamaluru V, Lockwood G, Bonnet D, and Newton J (2005) Lack of effect of rimonabant on the pharmacokinetics of digoxin. J Clin Pharmacol 45:1081.
19. Kruh GD and Belinsky MG (2003) The MRP family of drug efflux pumps. Oncogene 22:7537-7552. (Pubitemid 37487175)
20. Lange JH, Coolen HK, van Stuivenberg HH, Dijksman JA, Herremans AH, Ronken E, Keizer HG, Tipker K, McCreary AC, Veerman W, et al. (2004) Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB1 cannabinoid receptor antagonists. J Med Chem 47:627-643.
21. Lange JH, van Stuivenberg HH, Veerman W, Wals HC, Stork B, Coolen HK, McCreary AC, Adolfs TJ, and Kruse CG (2005) Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity. Bioorg Med Chem Lett 15:4794-4798. (Pubitemid 41354807)
22. Leslie EM, Deeley RG, and Cole SP (2005) Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216-237. (Pubitemid 40552845)
23. Loe DW, Almquist KC, Cole SP, and Deeley RG (1996) ATP-dependent 17β-estradiol 17-(β-D-Glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J Biol Chem 271:9683-9689.
24. Nies AT, Jedlitschky G, König J, Herold-Mende C, Steiner HH, Schmitt HP, and Keppler D (2004) Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 129:349-360.
25. Nies AT and Keppler D (2007) The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch 453:643-659. (Pubitemid 46192536)
26. Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Després JP, Kastelein JJ, Steinhubl SR, Kapadia S, et al. (2008) Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 299:1547-1560. (Pubitemid 351482794)
27. Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, and Piwnica- Worms D (1999) Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA 96:3900-3905. (Pubitemid 29169008)
28. Russel FG, Koenderink JB, and Masereeuw R (2008) Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol Sci 29:200-207.
29. Scheffer GL, Kool M, de Haas M, de Vree JM, Pijnenborg AC, Bosman DK, Elferink RP, van der Valk P, Borst P, and Scheper RJ (2002) Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest 82:193-201. (Pubitemid 34160456)
30. Smeets PH, van Aubel RA, Wouterse AC, van den Heuvel JJ, and Russel FG (2004) Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. J Am Soc Nephrol 15:2828-2835. (Pubitemid 41103391)
31. Tam J, Vemuri VK, Liu J, Bátkai S, Mukhopadhyay B, Godlewski G, Osei-Hyiaman D, Ohnuma S, Ambudkar SV, Pickel J, et al. (2010) Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 120:2953-2966.
32. Turpault S, Kanamaluru V, Lockwood GF, Bonnet D, and Newton J (2006) Rimonabant pharmacokinetics in healthy and obese subjects. Clin Pharmacol Ther 79:50.
33. Van Aubel RA, Hartog A, Bindels RJ, Van Os CH, and Russel FG (2000) Expression and immunolocalization of multidrug resistance protein 2 in rabbit small intestine. Eur J Pharmacol 400:195-198. (Pubitemid 30438726)
34. Van Aubel RA, Koenderink JB, Peters JG, Van Os CH, and Russel FG (1999) Mechanisms and interaction of vinblastine and reduced glutathione transport in membrane vesicles by the rabbit multidrug resistance protein Mrp2 expressed in insect cells. Mol Pharmacol 56:714-719. (Pubitemid 29491172)
35. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, and Russel FG (2002) The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 13:595-603. (Pubitemid 34183923)
36. Vollmer RR, Cavero I, Ertel RJ, Solomon TA, and Buckley JP (1974) Role of the central autonomic nervous system in the hypotension and bradycardia induced by (-)-Δ9-transtetrahydrocannabinol. J Pharm Pharmacol 26:186-192.
37. Yu XQ, Xue CC, Wang G, and Zhou SF (2007) Multidrug resistance associated proteins as determining factors of pharmacokinetics and pharmacodynamics of drugs. Curr Drug Metab 8:787-802. (Pubitemid 350238908)
38. Zelcer N, Huisman MT, Reid G, Wielinga P, Breedveld P, Kuil A, Knipscheer P, Schellens JH, Schinkel AH, and Borst P (2003) Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem 278:23538-23544. (Pubitemid 36830173)
39. Zeng H, Liu G, Rea PA, and Kruh GD (2000) Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res 60:4779-4784.
40. Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG, and Li Y (2008) Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 15:1981-2039.